Zambon Spa
Clinical trials sponsored by Zambon Spa, explained in plain language.
-
Inhaled drug shows promise for lung transplant rejection in phase 3 trial
Disease control CompletedThis study tested whether adding an inhaled form of cyclosporine A (L-CsA) to standard treatment helps people who have chronic lung rejection after a double lung transplant. The trial included 169 adults who had their transplant at least a year earlier. The main goal was to see i…
Phase: PHASE3 • Sponsor: Zambon SpA • Aim: Disease control
Last updated May 17, 2026 06:59 UTC
-
Inhaled drug shows promise for lung transplant patients with chronic rejection
Disease control CompletedThis study tested an inhaled form of cyclosporine A (a drug that suppresses the immune system) added to standard care for people who had a single lung transplant and developed chronic lung rejection. The goal was to see if the drug could improve lung function over 48 weeks. The t…
Phase: PHASE3 • Sponsor: Zambon SpA • Aim: Disease control
Last updated May 17, 2026 06:47 UTC
-
New hope for stubborn coughs: NAC beats placebo in major trial
Symptom relief CompletedThis study tested whether a one-week course of intravenous N-acetylcysteine (NAC) helps adults with respiratory diseases cough up thick mucus more easily. 333 hospitalized patients in China received either NAC, an active comparator (ambroxol), or a placebo. Results showed NAC was…
Phase: PHASE3 • Sponsor: Zambon SpA • Aim: Symptom relief
Last updated May 14, 2026 12:03 UTC